Ritesh R Kotecha1, Ronan Flippot2, Taylor Nortman1, Annalisa Guida2,3, Sujata Patil4, Bernard Escudier2, Robert J Motzer1, Laurence Albiges2, Martin H Voss1. 1. 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. 2Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France. 3. 3Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy; and. 4. 4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Metastatic renal cell carcinoma (mRCC) management guidelines recommend brain imaging if clinically indicated and the rate of occult central nervous system (CNS) metastasis is not well-defined. Early detection could have major therapeutic implications, because timely interventions may limit morbidity and mortality. PATIENTS AND METHODS: A retrospective review was performed to characterize patients with mRCC incidentally diagnosed with asymptomatic brain metastases during screening for clinical trial participation at Gustave Roussy and Memorial Sloan Kettering Cancer Center. Descriptive statistics and time-to-event methods were used to evaluate the cohort. RESULTS: Across 68 clinical trials conducted between 2001 and 2019 with a median 14.1-month follow-up, 72 of 1,689 patients (4.3%) with mRCC harbored occult brain metastases. The International Metastatic RCC Database Consortium (IMDC) risk status was favorable (26%), intermediate (61%), and poor (13%), and 86% of patients had ≥2 extracranial sites of disease, including lung metastases in 92% of patients. CNS involvement was multifocal in 38.5% of patients, and the largest brain metastasis was >1 cm in diameter in 40% of the cohort. Localized brain-directed therapy was pursued in 93% of patients, predominantly radiotherapy. Median overall survival was 10.3 months (range, 7.0-17.9 months), and the 1-year overall survival probability was 48% (95% CI, 37%-62%). IMDC risk and number or size of lesions did not correlate with survival (log-rank, P=.3, P=.25, and P=.067, respectively). CONCLUSIONS: This large multi-institutional mRCC cohort study identified occult brain metastasis in a notable proportion of patients (4.3%) and highlights that the risk of asymptomatic CNS involvement extends to those with favorable risk features per IMDC risk assessment. These data provide rationale for brain screening in patients with advanced RCC.
BACKGROUND: Metastatic renal cell carcinoma (mRCC) management guidelines recommend brain imaging if clinically indicated and the rate of occult central nervous system (CNS) metastasis is not well-defined. Early detection could have major therapeutic implications, because timely interventions may limit morbidity and mortality. PATIENTS AND METHODS: A retrospective review was performed to characterize patients with mRCC incidentally diagnosed with asymptomatic brain metastases during screening for clinical trial participation at Gustave Roussy and Memorial Sloan Kettering Cancer Center. Descriptive statistics and time-to-event methods were used to evaluate the cohort. RESULTS: Across 68 clinical trials conducted between 2001 and 2019 with a median 14.1-month follow-up, 72 of 1,689 patients (4.3%) with mRCC harbored occult brain metastases. The International Metastatic RCC Database Consortium (IMDC) risk status was favorable (26%), intermediate (61%), and poor (13%), and 86% of patients had ≥2 extracranial sites of disease, including lung metastases in 92% of patients. CNS involvement was multifocal in 38.5% of patients, and the largest brain metastasis was >1 cm in diameter in 40% of the cohort. Localized brain-directed therapy was pursued in 93% of patients, predominantly radiotherapy. Median overall survival was 10.3 months (range, 7.0-17.9 months), and the 1-year overall survival probability was 48% (95% CI, 37%-62%). IMDC risk and number or size of lesions did not correlate with survival (log-rank, P=.3, P=.25, and P=.067, respectively). CONCLUSIONS: This large multi-institutional mRCC cohort study identified occult brain metastasis in a notable proportion of patients (4.3%) and highlights that the risk of asymptomatic CNS involvement extends to those with favorable risk features per IMDC risk assessment. These data provide rationale for brain screening in patients with advanced RCC.
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Börje Ljungberg; Laurance Albiges; Yasmin Abu-Ghanem; Karim Bensalah; Saeed Dabestani; Sergio Fernández-Pello; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Teele Kuusk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Thomas Powles; Michael Staehler; Rana Tahbaz; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2019-02-23 Impact factor: 20.096
Authors: Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Brian Shuch; Jeff C La Rochelle; Tobias Klatte; Stephen B Riggs; Weiqing Liu; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Ethan A Ferrel; Andrew T Roehrig; Erin A Kaya; Jonathan D Carlson; Benjamin C Ling; Aaron Wagner; Alexander R MacKay; Jason A Call; John J Demakas; Wayne T Lamoreaux; Robert K Fairbanks; Barton S Cooke; Ben Peressini; Christopher M Lee Journal: Int J Mol Sci Date: 2016-03-18 Impact factor: 5.923
Authors: Landon C Brown; Kunal Desai; Wei Wei; Emily N Kinsey; Chester Kao; Daniel J George; Brian I Rini; Moshe C Ornstein; Tian Zhang Journal: J Immunother Cancer Date: 2021-09 Impact factor: 12.469
Authors: Hamid Emamekhoo; Mark R Olsen; Bradley C Carthon; Alexandra Drakaki; Ivor J Percent; Ana M Molina; Daniel C Cho; Johanna C Bendell; Lucio N Gordan; Arash Rezazadeh Kalebasty; Daniel J George; Thomas E Hutson; Edward R Arrowsmith; Joshua Zhang; Jesus Zoco; Jennifer L Johansen; David K Leung; Scott S Tykodi Journal: Cancer Date: 2021-11-16 Impact factor: 6.921